Abstract
Background
Scavenger receptors (SRs) play a pivotal role in atherogenesis. The mechanism of atherosclerosis, which is specific to hemodialysis (HD) patients, was studied on the basis of SR gene expressions.
Methods
The gene expressions of SR type A (SR-A) and CD36 were studied in peripheral monocytes by real-time reverse transcription polymerase chain reaction. Data were compared between HD (n = 30) and age-matched control subjects (n = 10). Serum levels of macrophage colony-stimulating factor (M-CSF) were measured with enzyme-linked immunosorbent assay to test its role in SR expression. The statistical differences and associations between two continuous variables were assessed using the Mann-Whitney U test and Pearson's correlation coefficient, respectively.
Results
The relative quantities of SR mRNAs were significantly greater in HD patients than in controls [median (interquartile range): SR-A, 1.67 (0.96-2.76) vs. 0.90 (0.60-1.04), p = 0.0060; CD36, 1.09 (0.88-1.74) vs. 0.74 (0.64-0.99), p = 0.0255]. The serum concentration of M-CSF was significantly higher in HD patients than in controls [1, 121 (999-1,342) vs. 176 (155-202) pg/ml, p < 0.0001]. In addition, the relative quantity of M-CSF mRNA was significantly greater in HD patients than in controls [0.79 (0.42-1.53) vs. 0.42 (0.28-0.66), p = 0.0392]. The serum M-CSF levels were positively correlated with both the relative quantity of SR-A mRNA (r2 = 0.1681, p = 0.0086) and that of CD36 mRNA (r2 = 0.1202, p = 0.0284) in all subjects (n = 40).
Conclusion
HD patients are predisposed to atherosclerosis as a consequence of their enhanced monocyte SR expressions. SRs and M-CSF are potential therapeutic targets for atherosclerosis in this high-risk population.
Key Words: Cardiovascular disease, Colony-stimulating factor-1 receptor, Macrophage colony-stimulating factor, Real-time reverse transcription polymerase chain reaction
Introduction
Chronic kidney disease (CKD) is linked to an increased risk of atherosclerosis, and the prevalence and incidence of cardiovascular disease (CVD) in CKD patients are much higher than in the healthy population [1,2,3,4]. The increased CVD risk in CKD patients may be a consequence of hypertension (HTN) due to activation of the renin-angiotensin-aldosterone system [5], hypercalcification of vessels associated with abnormal metabolism of calcium and phosphorus [6,7], the specific dyslipidemia of CKD, and so on [2,8,9,10]. As far as hemodialysis (HD) patients are concerned, the following factors are also involved: activation of platelet aggregation due to shear stress in the extracorporeal circulation [11] and overproduction of inflammatory cytokines by lymphocytes or monocytes, possibly due to endotoxin contamination and contact with the dialysis membrane [12,13,14]. Although previous researchers have identified numerous clinical factors relevant to the development of atherosclerosis in CKD and HD patients, they have not studied the mechanisms of atherosclerosis that are specific to HD patients on the basis of molecular biology.
In the 1980s, Steinberg [15] described the oxidized low-density lipoprotein (ox-LDL) and scavenger receptor (SR) hypothesis, and Ross [16] proposed the vascular injury hypothesis. Both suggested that atherosclerosis is a chronic inflammatory disease that insidiously develops at the site of damaged endothelial cells. In the 1990s, Kodama et al. [17] cloned the SR gene, thereby establishing the molecular and cellular basis for the mechanism of atherosclerosis. The SRs are constitutively expressed in monocyte-macrophage lineage cells and have diverse functions, among which their involvement in atherosclerosis is of great importance. The receptors are classified into six major subtypes on the basis of their molecular structure and distribution in tissues. Among them, SR type A (SR-A) and CD36, which is a member of SR type B, play pivotal roles in the development of atherosclerosis. SR-A and CD36 in circulating monocytes phagocytose atherogenic ox-LDL in an unregulated manner, resulting in the formation of foam cells under the endothelium, which is thought to be the earliest stage of atherosclerosis [15,16]. Using SR-A knockout mice and dyslipidemic mice, Robbins et al. [18] showed that SR-A plays essential roles in both the phagocytosis of ox-LDL by macrophages and the development of atherosclerosis. Nevertheless, although the status of SR expression in circulating monocytes may provide us with new clues as to why atherosclerosis is accelerated in HD patients, this is not fully understood in the clinical setting.
We hypothesized that HD patients are predisposed to atherosclerosis at the molecular level, and we tested the hypothesis with special reference to SR expression in peripheral monocytes. In addition, we focused on the role of macrophage colony-stimulating factor (M-CSF), as several previous studies found that serum M-CSF concentration was greatly increased in CKD and HD patients [19,20], and that the expression of SR in the human monocyte lineage cell line increased with increasing M-CSF concentration in the culture medium [21].
Materials and Methods
Study Design
This was a cross-sectional study. HD subjects were enrolled into the study at the time of routine outpatient care in Tokyo Women's University Hospital and Saito Memorial Hospital. Healthy control subjects were recruited from the staff of Tokyo Women's Medical University Hospital. The study was approved by the institutional review board of Tokyo Women's Medical University Hospital (certificate number 2753, Tokyo Women's Medical University) and conducted in accordance with the Declaration of Helsinki Principles on Human Experimentation. Informed consent was obtained from all subjects.
Blood Sampling and Laboratory Measurements
Whole blood was collected in a container with EDTA-2 kalium (2 ml) for whole blood cell count and in a container with no anticoagulant agents (10 ml) for other laboratory measurements at the start of HD or before breakfast in the morning. Four of these 10 ml were immediately processed according to the manufacturer's instructions for the magnetically labeled Whole Blood CD14+ MicroBeads (Miltenyi Biotec, Cologne, Germany), and total RNA was extracted from the eluted CD14+ monocytes. The remaining blood was separated into serum and blood cells, and the serum was stored at −80°C until assayed. Whole blood cell count and routine laboratory data were measured according to the conventional methods in the laboratory of Tokyo Women's Medical University. The electronic medical charts of all subjects were reviewed to determine the presence of comorbidities such as CKD, HTN, diabetes mellitus (DM), hyperlipidemia, and CVD. HTN was defined as a systolic blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg, or use of antihypertensive agents at baseline. DM was defined as a diagnosis of DM prior to baseline, or the use of oral antidiabetic agents or insulin at baseline. Hyperlipidemia was defined as a serum total cholesterol concentration ≥230 mg/dl in the overnight fasting state. CVD included a past history of cerebral infarction, cerebral bleeding, ischemic heart disease, and peripheral vascular disease.
Quantitative Real-Time Reverse Transcription Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from the CD14+ monocytes using ISOGEN (Wako Pure Chemical Industries, Tokyo, Japan) according to the manufacturer's instructions. Total RNA was determined by ultraviolet absorbance at 260 nm. The purity of the isolated RNA was evaluated, measuring the ratio of absorbance at 260 and 280 nm. RNA quality from each sample was assessed by measurement of the optical density 260/280 ratio with a target optical density ratio >1.7. Extracted RNA from all samples was stored at −80°C. cDNA was generated from 300 ng of total RNA using an all-in-one kit and an RT2 First Strand Kit (Qiagen, Japan), and qRT-PCRs were performed in triplicate in 96-well plates with an AB 7500 Real-Time PCR system (Applied Biosystems, Foster City, Calif., USA) using RT2 SYBR Green qPCR Mastermix (Qiagen). Primers were purchased from SABiosciences for M-CSF (catalog number PPH00124B, product size 105 bp), C-FMS (CSF1R) (catalog number PPH00191F, product size 95 bp), SR-A (catalog number PPH01357, product size 76 bp), CD36 (catalog number PPH001356A, product size 121 bp), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (catalog number PPH00150F, product size 175 bp). These primers were designed for SYBR Green qRT-PCR applications, and their experimentally verified design algorithm yielded gene-specific qRT-PCR assays. Amplification was conducted for 40 cycles (95°C for 30 s and 60°C for 60 s), according to the manufacturer's instructions. M-CSF mRNA, C-FMS mRNA, SR-A mRNA, and CD36 mRNA expression levels in peripheral CD14+ monocytes were measured by qRT-PCR, using the comparative cycle threshold (ΔΔCt) method. GAPDH was chosen as an endogenous reference gene to adjust for variations in gene amplification efficiencies among samples, and thus a sample ΔCt (target gene Ct - GAPDH Ct) was calculated (e.g., 2sample SR-A Ct / 2sample GAPDH Ct = 2sample SR-A Ct - GAPDH Ct = 2sample SR-A ΔCt). Next, the average of target gene ΔCts from 10 healthy samples was set as the calibration level of the target gene ΔCt, and thus a sample ΔΔCt (sample target gene ΔCt - calibration ΔCt) was calculated (e.g., 2sample SR-A ΔCt / 2calibration SR-A ΔCt = 2sample SR-A ΔCt - calibration ΔCt = 2sample SR-A ΔΔCt). This fold difference between the sample target gene ΔCt and the calibration ΔCt (-2ΔΔCt) was used as an index of relative target gene expression. The amplification efficiencies of M-CSF primer, C-FMS primer, SR-A primer, CD36 primer and GAPDH primer sets, which were confirmed to be approximately equal before the study, were analyzed using serial dilutions of RNA, as the equal amplification efficiencies of the target and endogenous reference mRNA allowed for the ΔΔCt method [22,23,24].
Measurement of Serum M-CSF Concentration
The serum concentration of M-CSF was measured using commercially available quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kits, following the manufacturer's standard protocol: Quantikine ELISA Human M-CSF Immunoassay (R&D Systems, USA).
Statistics
Data were expressed as median and interquartile range, unless otherwise stated. Statistical analyses were performed using the Mann-Whitney U test for continuous variables and the χ2 test for proportions. Common log transformation was applied when associations between the relative quantities of mRNA and the serum levels of M-CSF were assessed using Pearson's correlation coefficient, as those data were not normally distributed. All statistical analyses were performed using JMP 11 (SAS Institute Japan, Tokyo, Japan). All presented probability values are two-sided, and a p value <0.05 was considered to be statistically significant.
Results
Demographic and Laboratory Data of HD Patients
We studied 30 HD patients [14 men, 16 women; age 62 (55-67) years] and 10 control subjects [4 men, 6 women; age 60 (51-62) years]. The control subjects were age-matched and confirmed to have no CKD, DM, or CVD. The demographics and clinical characteristics of the chronic HD and control subjects are shown in table 1. HD duration was rather wide [67 (15-289) months], and the proportions of HD patients with DM or HTN were 26.7 and 73.3%, respectively. HTN patients were taking one or some antihypertensive drugs, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and calcium channel blockers. Eleven (36.7%) had been affected by CVD, including cerebral infarction, cerebral bleeding, ischemic heart disease, and peripheral vascular disease.
Table 1.
Demographics and laboratory data of the study subjects
| HD patients | Controls | |
|---|---|---|
| Subjects | 30 | 10 |
| Men | 14 (47%) | 4 (40%) |
| Age, years | 62 (55–67) | 60 (51–62) |
| HD duration, months | 67 (15–289) | – |
| DM | 8 (27%) | 0 (0%) |
| CVD | 11 (37%) | 0 (0%) |
| HTN | 22 (73%) | 5 (50%) |
| Use of ARB or ACEI | 19 (63%) | 5 (50%) |
| Use of calcium channel blocker | 16 (53%) | 2 (20%) |
| Use of statins | 17 (57%) | 1 (10%) |
| White blood cells, ×103/µl | 5.17 (4.07–6.71) | 5.12 (4.37–5.88) |
| Red blood cells, ×104/µl | 372 (359–409) | 460 (418–482) |
| Hemoglobin, g/dl | 10.8 (10.4–11.6) | 13.6 (13.2–14.4) |
| Hematocrit, % | 34.9 (33.7–37.2) | 40.9 (39.2–43.5) |
| Platelets, ×104/µl | 14.8 (12.3–20.4) | 23.3 (19.0–29.9) |
| Serum albumin, g/dl | 3.8 (3.4–4.0) | 4.3 (4.1–4.7) |
| Serum urea nitrogen, mg/dl | 65.0 (53.0–71.8) | 17.1 (11.2–18.5) |
| Serum creatinine, mg/dl | 11.1 (8.0–12.9) | 0.68 (0.60–0.79) |
| Serum calcium, mg/dl | 8.7 (8.4–9.4) | 9.3 (9.2–9.6) |
| Serum phosphorus, mg/dl | 5.1 (4.4–6.0) | 3.5 (3.4–3.8) |
| Serum C-reactive protein, mg/dl | 0.09 (0.05–0.14) | 0.04 (0.04–0.09) |
| Serum total cholesterol, mg/dl | 136 (125–161) | 195 (191–207) |
| Serum LDL-C, mg/dl | 67 (55–80) | 113 (94–129) |
| Serum HDL-C, mg/dl | 46 (32–61) | 70 (61–72) |
| Serum triglycerides, mg/dl | 198 (164–235) | 78 (61–88) |
Data are expressed as n, n (%), or median (interquartile range).
ACEI = Angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
SR-A and CD36 Gene Expressions in Peripheral Monocytes (qRT-PCR Analyses)
The comparisons of the relative quantities of SR-A and CD36 mRNAs in peripheral CD14+ monocytes between HD and control subjects are shown in figures 1a and b, respectively. SR-A gene expression was almost two-fold greater in the HD patients than in the controls [1.67 (0.96-2.76) vs. 0.90 (0.60-1.04), p = 0.0060]. CD36 gene expression was significantly greater in the HD patients than in the controls, but the group difference was smaller than that in SR-A gene expression [1.09 (0.88-1.74) vs. 0.74 (0.64-0.99), p = 0.0255].
Fig. 1.
Comparisons of the relative quantities of mRNA of SR-A (a) and CD36 (b). Data are visualized as box-and-whisker plots. Horizontal bars in boxes indicate median values and the height of boxes indicates the interquartile ranges of data. Error bars indicate standard deviations of data. Asterisks indicate that the differences between HD patients (P) and controls (C) are statistically significant (p < 0.05). a The relative quantity of SR-A mRNA was significantly greater in the HD patients than in the controls. b The relative quantity of CD36 mRNA was significantly greater in the HD patients than in the controls.
Serum M-CSF Concentration, and Gene Expressions of M-CSF and C-FMS in Peripheral Monocytes
The serum concentration of M-CSF was nearly six-fold greater in the HD patients than in the controls [1, 121 (999-1,342) vs. 176 (155-202) pg/ml, p < 0.0001]. The relative quantity of M-CSF mRNA was approximately two-fold greater in the HD patients than in the controls [0.79 (0.42-1.53) vs. 0.42 (0.28-0.66), p = 0.0392], whereas that of C-FMS mRNA did not differ between the HD and control subjects [0.71 (0.54-1.00) vs. 0.79 (0.64-1.35), p = 0.5220]. These results are shown in figure 2.
Fig. 2.
Serum M-CSF level (a) and gene expressions of M-CSF (b) and C-FMS (c) in peripheral CD14+ monocytes. Data are visualized as box-and-whisker plots. Horizontal bars in boxes indicate median values and the height of boxes indicates the interquartile ranges of data. Error bars indicate standard deviations of data. Asterisks indicate that the differences between the HD patients (P) and controls (C) are statistically significant (p < 0.05). a Serum M-CSF concentration was significantly greater in the HD patients than in the controls. b, c The relative quantity of M-CSF mRNA was significantly greater in the HD patients than in the controls (b); however, that of C-FMS mRNA was not different between the HD and control subjects (c).
Correlations of Gene Expressions of Monocyte SRs and Serum M-CSF in Overall Samples
Among the overall (HD plus control) sample (n = 40), serum M-CSF concentration was significantly correlated with the relative quantity of SR-A mRNA (r2 = 0.168, p = 0.0086) and with that of CD36 mRNA (r2 = 0.120, p = 0.0284). These correlations are shown in figure 3. In addition, serum M-CSF concentration was significantly associated with the relative quantity of M-CSF mRNA (r2 = 0.148, p = 0.0142), but not with that of C-FMS mRNA (r2 = 4.727 × 10-5, p = 0.9664). Moreover, there was a significant correlation between the relative quantities of SR-A and CD36 mRNAs (r2 = 0.142, p = 0.0151).
Fig. 3.
Correlations of serum M-CSF concentration with gene expressions of SR-A (a) and CD36 (b). Common log transformation was applied in the correlation coefficient analysis, as the data were not normally distributed. Serum M-CSF concentration was significantly correlated with the relative quantities of SR-A mRNA (a; r2 = 0.168, p = 0.0086) and CD36 mRNA (b; r2 = 0.122, p = 0.0284) among the overall sample (n = 40).
Discussion
Our study has shown that the gene expressions of SR-A and CD36 in the peripheral monocytes of HD patients are enhanced in the resting state without any special extrinsic stimulation. In other words, this indicates that HD patients are more susceptible to atherosclerosis in the presence of increased concentrations of atherogenic lipoproteins such as ox-LDL [25,26]. Moreover, the study has shown that serum M-CSF concentration is extremely high in HD patients, raising the possibility that M-CSF plays a key role in stimulating monocyte SRs in HD patients.
Based on ‘the SR and ox-LDL hypothesis’ of Steinberg [15], the enhancement of monocyte SRs that we have observed in HD patients tends to support the notion that ‘HD patients are predisposed to atherosclerosis’. Therefore, it is important to understand why monocyte SR gene expression is stimulated in such patients. Among the known stimulators of SRs, we focused on the role of M-CSF, as serum M-CSF levels are reported to be strongly increased in HD patients [19,27]. M-CSF is pertinent to the differentiation and growth of monocyte-macrophage lineage cells, and therefore an excess of M-CSF may have the potential to cause SR overexpression in circulating monocytes. In vitro culture experiments using monocyte lineage cells have shown that the expression of the SR-A gene increased with increasing M-CSF concentration in the medium [21]. In fact, our present study showed that a higher concentration of serum M-CSF, which was possibly due to increased M-CSF gene expression in peripheral monocytes, was associated with increased SR gene expressions.
Why is serum M-CSF concentration so high in HD patients? First, M-CSF may accumulate in blood due to a decrease in urinary excretion. M-CSF forms a dimer of 85 kDa molecular weight in the blood and is in part excreted into urine [28]. However, Le Meur et al. [20] found no difference in urinary M-CSF excretion between non-renal failure patients and renal failure patients with significantly elevated blood M-CSF levels, and they speculated that an alteration in urinary excretion is an unlikely cause of strongly increased M-CSF. Second, the abnormality of the specific receptor for M-CSF (C-FMS) in monocyte lineage cells needs to be considered. The major metabolic pathways of blood cytokines are mediated by binding to specific cytokine receptors in effector cells, a process that leads to their rapid removal from blood [29]. Nevertheless, this study did not show that peripheral monocyte C-FMS gene expression significantly decreased in the HD patients as compared with the control subjects. Third, overproduction of the M-CSF gene in monocyte lineage cells warrants discussion. M-CSF is produced primarily in monocyte-macrophage lineage cells, and in fact, we observed a significant increase in monocyte M-CSF gene expression in the HD patients compared with the controls. Although M-CSF gene expression is expected to be downregulated in HD patients due to their extremely high serum M-CSF levels, such downregulation appears to be disrupted. Taken together, intracellular regulation of the M-CSF gene may be defective in the monocytes of HD patients, which could be one of the causes (or consequences) of the high serum concentration of M-CSF.
Our study has several limitations. First, the sample size was small, the range of HD duration was rather wide, and the study population was limited to Japanese subjects. Therefore, in order to validate and generalize our results, it will be necessary to examine data from more HD and control subjects who have heterogeneity of ethnicity and homogeneity of HD duration. Second, monocyte heterogeneity, e.g., the three different monocyte subsets selected by CD14+, such as Mon 1 (CD14++CD16-CCR2+), Mon 2 (CD14++CD16+CCR2+), and Mon 3 (CD14+CD16++CCR2-), might be relevant to CKD-associated atherosclerosis [30], but it was not considered in this study. Third, characterization of M-CSF molecules was not studied. Profiling of M-CSF molecules accumulating in uremic serum on physical, chemical, and biological bases will be necessary in the future. Lastly, this study did not address how SR functions, such as phagocytic action of ox-LDL, are substantively increased in HD patients who manifest enhanced SR gene expressions. This is now under investigation in our laboratory, using ligand blot and flow cytometric analysis.
In conclusion, monocyte SR gene expressions are enhanced in HD patients in the resting state. M-CSF contributes to the enhancement of SR expressions, as both serum concentration and gene expression of M-CSF are significantly increased in HD patients. The abnormality of the SR gene expressions suggests that HD patients are susceptible to atherogenic lipoproteins such as ox-LDL, based on the currently established molecular mechanisms. Therefore, the attenuation of SR expressions in peripheral monocytes through the modulation of serum M-CSF levels is a likely therapeutic strategy for inhibiting the development of atherosclerosis in chronic HD patients. A prospective study is needed to clarify whether increased SR gene expression is a new risk factor linked to a higher incidence of CVD in HD patients.
Disclosure Statement
The authors declare no conflicts of interest.
Acknowledgments
We thank Dr. Kazunori Karasawa and Ms. Mayuko Hutaya of the Fourth Department of Internal Medicine, Tokyo Women's Medical University, for their valuable help.
References
- 1.Collado S, Coll E, Nicolau C, Pons M, Cruzado JM, Pascual J, Cases A. Carotid atherosclerotic disease predicts cardiovascular events in hemodialysis patients: a prospective study. PLoS One. 2015;10:e0127344. doi: 10.1371/journal.pone.0127344. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;27:339–352. doi: 10.1016/S0140-6736(13)60595-4. [DOI] [PubMed] [Google Scholar]
- 3.Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–2169. doi: 10.1161/01.CIR.0000095676.90936.80. [DOI] [PubMed] [Google Scholar]
- 4.Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, Saito Y, Ota H, Nose T. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006;69:1264–1271. doi: 10.1038/sj.ki.5000284. [DOI] [PubMed] [Google Scholar]
- 5.Campese VM, Park J. The kidney and hypertension: over 70 years of research. J Nephrol. 2006;19:691–698. [PubMed] [Google Scholar]
- 6.Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2008;19:213–216. doi: 10.1681/ASN.2007080854. [DOI] [PubMed] [Google Scholar]
- 7.Schoppet M, Shroff RC, Hofbauer LC, Shanahan CMM. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int. 2008;73:384–390. doi: 10.1038/sj.ki.5002696. [DOI] [PubMed] [Google Scholar]
- 8.Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25:2615–2622. doi: 10.1161/01.ATV.0000188555.60475.c2. [DOI] [PubMed] [Google Scholar]
- 9.Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, Reitinger J, Pinter G, Utermann G, Dieplinger H. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol. 1995;6:110–120. doi: 10.1681/ASN.V61110. [DOI] [PubMed] [Google Scholar]
- 10.Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis. 2001;38(4 suppl 1):S30–S33. doi: 10.1053/ajkd.2001.27393. [DOI] [PubMed] [Google Scholar]
- 11.Ando M, Iwata A, Ozeki Y, Tsuchiya K, Akiba T, Nihei H. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int. 2002;62:1757–1763. doi: 10.1046/j.1523-1755.2002.00627.x. [DOI] [PubMed] [Google Scholar]
- 12.Takahashi T, Kubota M, Nakamura T, Ebihara I, Koide H. Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail. 2000;22:345–354. doi: 10.1081/jdi-100100878. [DOI] [PubMed] [Google Scholar]
- 13.Lonnemann G, Behme TC, Lenzner B, Floege J, Schulze M, Colton CK, Koch KM, Shaldon S. Permeability of dialyzer membranes to TNF alpha-inducing substances derived from water bacteria. Kidney Int. 1992;42:61–68. doi: 10.1038/ki.1992.261. [DOI] [PubMed] [Google Scholar]
- 14.Yao Q, Lindholm B, Stenvinkel P. Inflammation as a cause of malnutrition, atherosclerotic cardiovascular disease, and poor outcome in hemodialysis patients. Hemodial Int. 2004;8:118–129. doi: 10.1111/j.1492-7535.2004.01085.x. [DOI] [PubMed] [Google Scholar]
- 15.Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation. 1989;80:1070–1078. doi: 10.1161/01.cir.80.4.1070. [DOI] [PubMed] [Google Scholar]
- 16.Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999;340:115–126. doi: 10.1056/NEJM199901143400207. [DOI] [PubMed] [Google Scholar]
- 17.Kodama T, Freeman M, Rohrer L, Zabrecky J, Matsudaira P, Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature. 1990;343:531–535. doi: 10.1038/343531a0. [DOI] [PubMed] [Google Scholar]
- 18.Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Fuqueiredo JL, Gorbatov R, Sukhova GK, Gerhardt LM, Smyth D, Zavitz CC, Shikatani EA, Parsons M, Van Rooijen N, Lin HY, Husain M, Libby P, Nahrendorf M, Weisslender R, Swirski FK. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19:1166–1172. doi: 10.1038/nm.3258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ando M, Lundkvist I, Bergstrom J, Lindholm B. Enhanced scavenger receptor expression in monocyte-macrophages in dialysis patients. Kidney Int. 1996;49:773–780. doi: 10.1038/ki.1996.107. [DOI] [PubMed] [Google Scholar]
- 20.Le Meur Y, Fixe P, Aldigier JC, Leroux-Robert C, Praloran V. Macrophage colony stimulating factor involvement in uremic patients. Kidney Int. 1996;50:1007–1012. doi: 10.1038/ki.1996.402. [DOI] [PubMed] [Google Scholar]
- 21.Nikolic D, Calderon L, Du L, Post S. SR-A ligand and M-CSF dynamically regulate SR-A expression and function in primary macrophages via p38 MAPK activation. BMC Immunol. 2011;12:37. doi: 10.1186/1471-2172-12-37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Espitia CM, Zhao W, Saldarriaga O, Osorio Y, Harrison LM, Cappello M, Travi BL, Melby PC. Duplex real-time reverse transcriptase PCR to determine cytokine mRNA expression in a hamster model of New World cutaneous leishmaniasis. BMC Immunol. 2010;11:31. doi: 10.1186/1471-2172-11-31. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
- 24.Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3:1101–1108. doi: 10.1038/nprot.2008.73. [DOI] [PubMed] [Google Scholar]
- 25.Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G, Gazo A, Nai M, Romanini D, Bellomo G. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis? Kidney Int. 1994;45:876–883. doi: 10.1038/ki.1994.115. [DOI] [PubMed] [Google Scholar]
- 26.Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol. 1999;10:2177–2184. doi: 10.1681/ASN.V10102177. [DOI] [PubMed] [Google Scholar]
- 27.Ando M, Gafvels M, Bergstrom J, Lindholm B, Lundkvist I. Uremic serum enhances scavenger receptor expression and activity in the human monocytic cell line U937. Kidney Int. 1997;51:785–792. doi: 10.1038/ki.1997.110. [DOI] [PubMed] [Google Scholar]
- 28.Motoyoshi K. Biological activities and clinical application of M-CSF. Int J Hematol. 1998;67:109–122. doi: 10.1016/s0925-5710(98)00010-3. [DOI] [PubMed] [Google Scholar]
- 29.Bezbradica JS, Medzhitov R. Integration of cytokine and heterologous receptor signaling pathways. Nat Immunol. 2009;10:333–339. doi: 10.1038/ni.1713. [DOI] [PubMed] [Google Scholar]
- 30.Rogacev KS, Seiler S, Zawada AM. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. Eur Heart J. 2011;32:84–92. doi: 10.1093/eurheartj/ehq371. [DOI] [PubMed] [Google Scholar]